| Prev Close | 6.96 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 4.60 / 8.63 |
| Avg Volume | 1.31M |
| Exchange | NASDAQ |
| Shares Outstanding | 72.66M |
| Market Cap | 506.45M |
| EPS | -0.70 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Significant correlation between overall tumor biomarker response and achievement of the primary and secondary endpoints in pivotal study of AZEDRA
Investors eyeing a purchase of Progenics Pharmaceuticals, Inc. stock, but cautious about paying the going market price of $8.39/share, might benefit from considering selling puts among the alternative strategies at their disposal.
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the April 20th expiration.
Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.
A roundup of biotech names with actions pending at the FDA in coming weeks.
I've added to my positions in these names on yesterday's intraday silliness.
Top-line Data Expected in 3Q2018
Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the August 2018 expiration.
Sector M&A activity is likely to pick up next year benefiting the space.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
We are coming my favorite part of earnings season -- when these small-caps report.
The housing market will continue to improve over the next few years due to pent up demand.
Diversification is absolutely critical when investing in this sector.
Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise.
